글로벌 트랜스펙션 시약 및 장비 시장 – 2030년까지의 산업 동향 및 예측

트랜스펙션 시약 및 장비 시장 분석 및 통찰력

형질감염은 바이러스 및 비바이러스 방법을 통해 진핵 세포에 핵산을 도입하는 것을 포함합니다. 형질감염 방법은 음전하를 띤 막을 전달하는 과제를 극복할 수 있습니다. 인산칼슘 및 디에틸아미노에틸(DEAE)-덱스트란 또는 양이온성 지질 기반 시약과 같은 화학 물질은 외부 DNA 코팅과 반응합니다. 전체 음전하를 중화하고 분자에 양전하를 부여하여 DNA 전달을 허용합니다. 전기천공과 같은 물리적 방법은 전압을 적용하여 세포막에 미세한 기공을 만들어 DNA가 세포질로 직접 유입되도록 합니다. DEAE-덱스트란은 일시적 형질감염에 사용되지만 리포펙션은 안정적인 형질감염을 달성할 수 있으므로 장기적인 단백질 발현에 사용할 수 있습니다. 인산칼슘 매개 형질감염도 안정적인 형질감염에 사용할 수 있습니다. 바이러스 형질감염 방법은 높은 효율성을 달성하며 제약 제품 개발의 여러 단계에 사용됩니다.

형질감염 방법은 작물 보호 및 수확량 증가를 위한 농업, 풍미와 향을 강화하기 위한 합성 생물학 제품 생산, 단세포 단백질 강화 등 여러 가지 용도로 사용됩니다. 선진국과 개발도상국 모두에서 형질감염에 대한 수요가 증가했으며, 그 이유는 만성 질환의 증가 때문입니다. 형질감염 시장은 키메라 유전자에 대한 수요 증가와 단백질 생산에 생물제약품 활용으로 인해 성장하고 있습니다 . 이 시장은 신흥 시장 탐색, 시장 참여자의 전략적 이니셔티브, 정부 지원 증가로 인해 예측 기간 동안 성장할 것입니다.

높은 장비 비용, 형질감염 시약의 선택적 효과, 형질감염 방법으로 인한 세포 손상 등으로 인해 글로벌 형질감염 시약 및 장비 시장 성장이 제한될 것으로 예상됩니다.

시장 참여자들이 인수, 협력, 파트너십을 포함한 여러 전략적 이니셔티브를 채택하면서 시장이 성장하고 있습니다.

Data Bridge Market Research analyzes that the global transfection Reagent and equipment market is expected to reach the value of USD 2,284,494.00 thousand by 2030, at a CAGR of 9.6% during the forecast period.

Market Definition

The transfection method is used to introduce RNA, DNA or protein products in cells to alter the phenotype and genotype of the organism. The transfection method involves the new gene transfer or transferring a gene construct such as Clustered regularly interspaced short palindromic repeats (CRISPR) for genome editing purposes. Transfection has wide applications in the field of immunotherapy, gene therapy, and cell therapy, among others. Transfection involves both non-viral and viral-mediated transfection. The chemical and physical methods can achieve non–viral transfection. The most common chemical method used for transfection is calcium phosphate transfection, and liposome transfection, among others. Viral transfection yields high transfection efficiencies, and various types of physical methods employed for transfection include microinjection, biolistic particle delivery, and electroporation, among which electroporation provides high transfection efficiency. Transfection is of two types either it can be transient or stable transfection. For short-term gene expression studies such as gene knock-out studies, small-scale production transient transfection method is preferred; however, long-term research studies and large-scale protein production stable transfection methods are widely adopted.

Global Transfection Reagent and Equipment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• RISE IN THE PREVALENCE OF CHRONIC DISEASES

The prevalence of chronic diseases is increasing worldwide, leading to the demand for effective and accurate treatment. Transfection is used to deliver targeted modified genes to treat several genetic diseases. The transfection method is also used for the delivery of the CRISPR gene, which can enhance adaptive immunity and prevent an individual from different diseases.

The increasing cases of chronic diseases such as COVID-19 and other infectious diseases have led to the discovery of effective gene therapy products which can replace the defective gene with the correct gene. The transfection method is widely used for gene therapy, among others. As the demand for effective and accurate treatment is increasing worldwide, the demand for gene therapy and transfection method is also increasing. Moreover, several undergoing researches proving gene therapy to have the potential for chronic disease treatment are also increasing its demand among physicians and patients. This thus signifies that the rise in chronic disease prevalence is acting as a driver for the global transfection Reagent and equipment market growth.

• DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS

Synthetic biology is a new era of biology that incorporates the engineering principle into biology. Synthetic biology involves the chemical synthesis of DNA by combining the knowledge of genomics to reassemble the DNA genomes. The synthetic biology that sequences into the new genes involves genetic engineering, which incorporates the transfection method, among others. As the demand for synthetic biology products is increasing worldwide, the use of transfection products is also increasing.

The demand for synthetic biology products is increasing due to the increasing demand for effective and innovative products. The manufacturing of synthetic products enhances the demand for transfection products, as gene transfer can be accompanied by the transfection method, among others. Thus, this signifies that synthetic product development drives the global transfection Reagent and equipment market growth.

Restraint

• CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE

Some transfection methods have been reported to cause cell damage, reducing the reproducibility of the overall method. Among the several kinds of transfection procedures, electroporation has been reported to cause maximum cell damage as per the increase in voltage. This cell damage lowers the efficiency rate and impacts the ongoing project.

One of the most common side effects of the transfection procedure is cell damage which lowers the cells metabolic events and leads to cell death. This damaged cell can enhance the media toxicity and hence produces inappropriate results. Thus, this suggests that cell damage induced by the transfection procedure acts as a restraint for the global transfection Reagent and equipment market growth.

Opportunity

• EXPLORATION OF EMERGING MARKET

The transfection products have been shown as promising tools for the genetic engineering and proteomic industry. The top market for transfection products is in Europe and North America. By looking at the positive outcomes of these products, many market players are penetrating their roots in growing economies involving China and India, among others. The emerging market allows these market players to combat the loss that arises from the well-established market.

As emerging markets allow the market players to overcome the economic downturn specified to particular established markets, investment and exploration of emerging markets allow the market players to engage in the development and manufacturing of transfection products to attain lucrative growth. Thus, this signifies that exploring emerging markets is an opportunity to grow the global transfection Reagent and equipment market.

Challenge

• LONG APPROVAL PROCEDURE

The long approval procedure for transfection Reagent and instruments is a hindering agent for the growth of the transfection market. Transfection products are subjected to extensive regulations and have to monitor every time. The transfection products are widely used for the insertion of desired gene molecules in a particular cell line to obtain proteins and other biological compounds. This process is thus investigated and approved by the long and strict regulatory procedures. The long process required to get a positive result from every conducted clinical trial led to more time consumption and the investment of lots of money by market players.

The transfection Reagent are mostly subjected to 21CFR parts 210 and 211 U.S. FDA guidelines, according to which the manufacturers had to assure that the reagent manufactured meets the safety, packaging and processing characteristics proposed by the regulatory agencies. The owner or manufacturer has to submit licenses under section 351 of the PHS (Public Health Services) Act, which is quite a tedious procedure. Thus, this signifies that long approval procedures challenge the global transfection Reagent and equipment market growth.

Recent Developments

• In August 2021, Mirus Bio expanded the TransIT VirusGen platform for Good Manufacturing Practice (GMP) viral vector production to support cell and gene therapy development, process operations, and commercial production. The extension, referred to as TransIT VirusGen GMP Transfection Reagent, is designed to improve the packaging and delivery of vector DNA to suspension and adherent HEK 293 cell types to improve the production of recombinant adeno-associated viruses and lentiviral vectors.
• In April 2021, BOC Sciences announced the launch of two in vivo RNA transfection kits, namely siRNA in vivo transfection kits and mRNA in vivo transfection kits, suitable for in vivo transfection of siRNA and mRNA, respectively.

Global Transfection Reagent and Equipment Market Scope

Global transfection Reagent and equipment market is segmented into nine notable segments such as products, stage, methods, type, types of molecule, application, end user, organism, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

PRODUCTS

• INSTRUMENTS
• REAGENT & KITS

On the basis of products, the global transfection reagent and equipment market is segmented into instruments and reagent & kits.

STAGE

• RESEARCH
• PRECLINICAL
• CLINICAL PHASES
• COMMERCIAL

On the basis of stage, the global transfection reagent and equipment market is segmented into research, preclinical, clinical phases and commercial.

TYPE

• TRANSIENT TRANSFECTION REAGENT AND EQUIPMENT
• STABLE TRANSFECTION REAGENT AND EQUIPMENT

On the basis of type, the global transfection reagent and equipment market is segmented into transient transfection reagent and equipment and stable transfection reagent and equipment.

METHODS

• NON-VIRAL METHODS
• VIRAL METHODS

On the basis of methods, the global transfection reagent and equipment market is segmented into non-viral methods and viral methods.

TYPES OF MOLECULE

• PLASMID DNA
• DNA OLIGONUCLEOTIDES
• SMALL INTERFERING RNA (SIRNA)
• PROTEINS
• RIBONUCLEOPROTEIN COMPLEXES (RNPS)
• OTHERS

On the basis of types of molecule, the global transfection reagent and equipment market is segmented into plasmid DNA, DNA oligonucleotides, small interfering RNA (siRNA), proteins, ribonucleoprotein complexes (RNPs) and others.

ORGANISM

• BACTERIA
• MAMMALIAN CELLS
• FUNGI
• PLANTS
• VIRUS

On the basis of organism, the global transfection reagent and equipment market is segmented into bacteria, mammalian cells, fungi, plants and virus.

APPLICATION

• BY TYPE
  • IN VITRO APPLICATION
  • IN VIVO APPLICATION
  • BIOPRODUCTION
  • OTHERS
• BY INDUSTRY
  • AGRICULTURE
  • SYNTHETIC BIOLOGY
  • OTHERS

On the basis of application, the global transfection reagent and equipment market is segmented by type into in vitro application, in vivo application, bioproduction, others and by industry into agriculture, synthetic biology, others.

END USER

• BIOPHARMA
• CROS
• CMOS/CDMOS
• ACADEMIA
• HOSPITALS
• CLINICAL LABS
• OTHERS

On the basis of end user, the global transfection reagent and equipment market is segmented into biopharma, CROs, CMOs/ CDMOs, academia, hospitals, clinical labs and others.

DISTRIBUTION CHANNEL

• DIRECT TENDER
• RETAIL SALES
• OTHERS

On the basis of distribution channel, the global transfection Reagent and equipment market is segmented into direct tender, retail sales and others.

Global Transfection Reagent and Equipment Market Regional Analysis/Insights

The global transfection reagent and equipment market is categorized into many notable segments such as geography, products, stages, methods, type, types of molecule, application, end user, organism, and distribution channel.

The countries covered in this market report are U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Switzerland, Russia, Netherlands, Belgium, Turkey, and Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Philippines, Indonesia, and Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt, and Rest of the Middle East and Africa.

In 2023, the North America region is dominating due to the presence of key market players in the largest consumer market with high GDP. U.S is expected to grow due to rise in the prevalence of chronic and rare diseases leading to increase in the use of transfection reagent and equipment.

북미는 의료 분야에 대한 투자 증가로 인해 시장을 지배하고 있으며, 시장 성장을 촉진할 것으로 예상됩니다. 미국은 주요 기업의 강력한 입지로 인해 북미 지역을 지배합니다. 독일은 신흥 시장의 수요 증가와 확장으로 인해 유럽 지역을 지배합니다. 중국은 첨단 기술 프로세스에 대한 고객 성향이 증가함에 따라 아시아 태평양 지역을 지배합니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 글로벌 트랜스펙션 시약 및 장비 시장 점유율 분석

글로벌 트랜스펙션 시약 및 장비 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭 및 호흡, 응용 분야 우세, 제품 유형 수명선 곡선입니다. 제공된 위의 데이터 포인트는 글로벌 트랜스펙션 시약 및 장비 시장에 대한 회사의 초점과만 관련이 있습니다.

이 시장에서 운영되는 주요 기업 중 일부는 Mirus Bio LLC., Promega Corporation, Polyplus Transfection, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Altogen Biosystems, SBS Genetech, FUJIFILM Irvine Scientific(FUJIFILM Holdings Corporation의 자회사), Avanti Polar Lipids(Croda International Plc의 자회사), PerkinElmer chemagen Technologie GmbH(PerkinElmer Inc.의 자회사), Cytiva, Geno Technology Inc., USA, R&D Systems, Inc., Takara Bio Inc., Thermofisher Scientific Inc., Roche Molecular Systems, Inc.(F. Hoffmann-La Roche Ltd의 자회사), QIAGEN, OriGene Technologies, Inc., Applied Biological Materials Inc.(abm), Beckman Coulter, Inc.(Danaher의 자회사)입니다. Amyris, Codexis, Autolus, SignaGen Laboratories, Impossible Foods Inc., Genlantis Inc., Ginkgo Bioworks, Verve Therapeutics, Inc., Conagen, Inc., Poseida Therapeutics, Inc., Twist Bioscience 등이 있습니다.

SKU-1714